Market Cap 8.10B
Revenue (ttm) 12.82B
Net Income (ttm) 936.34M
EPS (ttm) N/A
PE Ratio 12.01
Forward PE 11.08
Profit Margin 7.31%
Debt to Equity Ratio -33.86
Volume 328,900
Avg Vol 923,760
Day's Range N/A - N/A
Shares Out 70.60M
Stochastic %K 14%
Beta 1.00
Analysts Sell
Price Target $143.00

Company Profile

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative se...

Industry: Medical Care Facilities
Sector: Healthcare
Phone: 720-631-2100
Address:
2000 16th Street, Denver, United States
SparkyReturns
SparkyReturns Dec. 22 at 5:21 PM
$ICU Dammit I should keep quiet. Now I gotta chase it to get more shares. This device will be a game-changer for kidney disease, sepsis, cardio-renal, and any disease with hyper-inflammation and cytokine storm. GL longs! $DVA $BAX $MCK $BDX
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 4:32 PM
Actionable Trade Alert for $DVA: Market Context: $DVA is currently trading at $116.15, showing a bearish sentiment as indicated by an RSI of 34.14, suggesting potential oversold conditions. The price is below both the 30-day MA (119.3) and the 50-day MA (121.8), reinforcing a bearish trend. The recent 60-day high of 134.59 and low of 113.97 indicates a range-bound market, providing a clear framework for potential trades. Directional Bias: Given the current RSI and position relative to MAs, we anticipate a short-term rebound towards the upper range. Trade Plan: - Suggested Entry: $116.15 - Stop Loss: $113.50 (below 60D low) - Take Profit Targets: 1. $120.00 (3.25% ROI) 2. $123.00 (5.00% ROI) 3. $136.00 (17.1% ROI) This plan capitalizes on the potential for a price recovery while maintaining a manageable risk. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Noname2022
Noname2022 Dec. 18 at 6:02 PM
$CRMD $FMS $DVA RWE similar to Phase III lockit trial efficacy This ISPOR paper/model was based on phase III trial and other assumptions https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2025/poster-session-4/the-clinical-value-and-cost-effectiveness-of-defencath-for-reducing-catheter-related-bloodstream-infections-in-adult-patients-receiving-hemodialysis-through-a-central-venous-catheter
1 · Reply
ZacksResearch
ZacksResearch Dec. 18 at 3:27 PM
$DVA holds steady — growth drivers vs. a real payer risk ⚖️ The stock is supported by a patient-centric model, Q3 revenue growth, and overseas expansion, but reliance on commercial payers remains a key overhang investors can’t ignore. Full bull/bear breakdown on DVA here 👉 https://www.zacks.com/stock/news/2806065/heres-why-you-should-hold-davita-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2806065-teaser-25394&ADID=SYND_STOCKTWITS_TWEET_2_2806065_TEASER_25394
0 · Reply
ZacksResearch
ZacksResearch Dec. 18 at 2:27 PM
Is $DVA poised for a turnaround after its mixed Q3 results? 🤔 Despite opening new centers and overseas growth, DVA lost 12.8% over six months, with ongoing concerns about reliance on commercial payers. However, its international expansion strategy and unique patient-centric model could drive future growth. Discover the full analysis here 👉 https://www.zacks.com/stock/news/2806065/heres-why-you-should-hold-davita-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2806065-body-25382&ADID=SYND_STOCKTWITS_TWEET_2_2806065_BODY_25382
0 · Reply
RyGuy_79
RyGuy_79 Dec. 18 at 1:51 PM
$CRMD $DVA I will actively avoid Davita for myself and my family members in the future so we don’t die from CRBSI due to their gross negligence.
0 · Reply
DrArmageddon
DrArmageddon Dec. 18 at 1:48 PM
$CRMD $DVA what are you waiting for DaVita : more mortality and more losing business. the business model of previous CEO is past and time to adopt innovative tool to boost your business. DaVita shareholders need to start emailing the management
0 · Reply
InvestorM
InvestorM Dec. 18 at 1:33 PM
0 · Reply
Noname2022
Noname2022 Dec. 18 at 1:13 PM
$CRMD $DVA $FMS $AKBA “Based on CorMedix’s analysis of the data available through September 30, 2025, compared to historical controls, use of DefenCath demonstrated an overall 72% reduction in CRBSI, and a 70% reduction in hospitalizations secondary to CRBSI.“ https://www.globenewswire.com/news-release/2025/12/18/3207654/0/en/CorMedix-Therapeutics-Announces-Positive-Data-From-Ongoing-Real-World-Evidence-Study-of-DefenCath.html
0 · Reply
Noname2022
Noname2022 Dec. 17 at 8:41 PM
$DVA $AKBA Average DVA patient on 16 medicarions per CIO, whats one more #patientcompliance https://www.healthcareittoday.com/2025/12/01/cio-podcast-episode-104-leveraging-ai-with-madhu-narasimhan/
0 · Reply
Latest News on DVA
DaVita Names New Leaders to Accelerate Care Transformation

Dec 11, 2025, 8:00 AM EST - 13 days ago

DaVita Names New Leaders to Accelerate Care Transformation


DaVita: More Volatile But Better Upside Than Fresenius

Dec 3, 2025, 9:30 AM EST - 21 days ago

DaVita: More Volatile But Better Upside Than Fresenius


DaVita Inc. to Participate in Fireside Chat with Wolfe Research

Nov 14, 2025, 4:16 PM EST - 5 weeks ago

DaVita Inc. to Participate in Fireside Chat with Wolfe Research


DaVita Inc. (DVA) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 7:46 PM EDT - 2 months ago

DaVita Inc. (DVA) Q3 2025 Earnings Call Transcript


DaVita Inc. 3rd Quarter 2025 Results

Oct 29, 2025, 4:05 PM EDT - 2 months ago

DaVita Inc. 3rd Quarter 2025 Results


DaVita Inc. Schedules 3rd Quarter 2025 Investor Conference Call

Oct 13, 2025, 2:00 PM EDT - 2 months ago

DaVita Inc. Schedules 3rd Quarter 2025 Investor Conference Call


DaVita: Aggressive Buybacks Despite Rising Cost Of Debt

Aug 20, 2025, 9:36 AM EDT - 4 months ago

DaVita: Aggressive Buybacks Despite Rising Cost Of Debt


DaVita Inc. (DVA) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 10:02 PM EDT - 5 months ago

DaVita Inc. (DVA) Q2 2025 Earnings Call Transcript


DaVita Inc. 2nd Quarter 2025 Results

Aug 5, 2025, 4:05 PM EDT - 5 months ago

DaVita Inc. 2nd Quarter 2025 Results


DaVita Inc. Schedules 2nd Quarter 2025 Investor Conference Call

Jul 17, 2025, 5:37 PM EDT - 5 months ago

DaVita Inc. Schedules 2nd Quarter 2025 Investor Conference Call


DaVita: International Expansion And Buybacks Will Boost Returns

May 27, 2025, 11:30 AM EDT - 7 months ago

DaVita: International Expansion And Buybacks Will Boost Returns


DaVita Inc. Announces Offering of $750 Million Senior Notes

May 20, 2025, 8:51 AM EDT - 7 months ago

DaVita Inc. Announces Offering of $750 Million Senior Notes


DaVita Inc. (DVA) Q1 2025 Earnings Call Transcript

May 12, 2025, 9:41 PM EDT - 8 months ago

DaVita Inc. (DVA) Q1 2025 Earnings Call Transcript


DaVita First-Quarter 2025 Financial Results: Just the Numbers

May 12, 2025, 4:51 PM EDT - 8 months ago

DaVita First-Quarter 2025 Financial Results: Just the Numbers


DaVita Inc. 1st Quarter 2025 Results

May 12, 2025, 4:05 PM EDT - 8 months ago

DaVita Inc. 1st Quarter 2025 Results


DaVita Inc. Schedules 1st Quarter 2025 Investor Conference Call

Apr 30, 2025, 11:00 AM EDT - 8 months ago

DaVita Inc. Schedules 1st Quarter 2025 Investor Conference Call


DaVita Says Ransomware Attack Affecting Some Operations

Apr 14, 2025, 7:35 AM EDT - 9 months ago

DaVita Says Ransomware Attack Affecting Some Operations


Dialysis firm DaVita hit by ransomware attack

Apr 14, 2025, 7:33 AM EDT - 9 months ago

Dialysis firm DaVita hit by ransomware attack


Berkshire Hathaway sells another 750,000 DaVita shares

Feb 19, 2025, 8:05 PM EST - 11 months ago

Berkshire Hathaway sells another 750,000 DaVita shares


DaVita Inc. (DVA) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 8:19 PM EST - 11 months ago

DaVita Inc. (DVA) Q4 2024 Earnings Call Transcript


Berkshire sells some DaVita shares, cuts stake to 45%

Feb 13, 2025, 8:13 PM EST - 11 months ago

Berkshire sells some DaVita shares, cuts stake to 45%


DaVita forecasts 2025 profit below estimates, shares plummet

Feb 13, 2025, 6:07 PM EST - 11 months ago

DaVita forecasts 2025 profit below estimates, shares plummet


DaVita Inc. 4th Quarter 2024 Results

Feb 13, 2025, 4:05 PM EST - 11 months ago

DaVita Inc. 4th Quarter 2024 Results


DaVita Inc. Schedules 4th Quarter 2024 Investor Conference Call

Jan 30, 2025, 11:55 AM EST - 11 months ago

DaVita Inc. Schedules 4th Quarter 2024 Investor Conference Call


DaVita Inc. (DVA) Q3 2024 Earnings Call Transcript

Oct 29, 2024, 9:27 PM EDT - 1 year ago

DaVita Inc. (DVA) Q3 2024 Earnings Call Transcript


DaVita misses third-quarter profit estimates on higher costs

Oct 29, 2024, 4:23 PM EDT - 1 year ago

DaVita misses third-quarter profit estimates on higher costs


DaVita Inc. 3rd Quarter 2024 Results

Oct 29, 2024, 4:05 PM EDT - 1 year ago

DaVita Inc. 3rd Quarter 2024 Results


SparkyReturns
SparkyReturns Dec. 22 at 5:21 PM
$ICU Dammit I should keep quiet. Now I gotta chase it to get more shares. This device will be a game-changer for kidney disease, sepsis, cardio-renal, and any disease with hyper-inflammation and cytokine storm. GL longs! $DVA $BAX $MCK $BDX
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 4:32 PM
Actionable Trade Alert for $DVA: Market Context: $DVA is currently trading at $116.15, showing a bearish sentiment as indicated by an RSI of 34.14, suggesting potential oversold conditions. The price is below both the 30-day MA (119.3) and the 50-day MA (121.8), reinforcing a bearish trend. The recent 60-day high of 134.59 and low of 113.97 indicates a range-bound market, providing a clear framework for potential trades. Directional Bias: Given the current RSI and position relative to MAs, we anticipate a short-term rebound towards the upper range. Trade Plan: - Suggested Entry: $116.15 - Stop Loss: $113.50 (below 60D low) - Take Profit Targets: 1. $120.00 (3.25% ROI) 2. $123.00 (5.00% ROI) 3. $136.00 (17.1% ROI) This plan capitalizes on the potential for a price recovery while maintaining a manageable risk. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Noname2022
Noname2022 Dec. 18 at 6:02 PM
$CRMD $FMS $DVA RWE similar to Phase III lockit trial efficacy This ISPOR paper/model was based on phase III trial and other assumptions https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2025/poster-session-4/the-clinical-value-and-cost-effectiveness-of-defencath-for-reducing-catheter-related-bloodstream-infections-in-adult-patients-receiving-hemodialysis-through-a-central-venous-catheter
1 · Reply
ZacksResearch
ZacksResearch Dec. 18 at 3:27 PM
$DVA holds steady — growth drivers vs. a real payer risk ⚖️ The stock is supported by a patient-centric model, Q3 revenue growth, and overseas expansion, but reliance on commercial payers remains a key overhang investors can’t ignore. Full bull/bear breakdown on DVA here 👉 https://www.zacks.com/stock/news/2806065/heres-why-you-should-hold-davita-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2806065-teaser-25394&ADID=SYND_STOCKTWITS_TWEET_2_2806065_TEASER_25394
0 · Reply
ZacksResearch
ZacksResearch Dec. 18 at 2:27 PM
Is $DVA poised for a turnaround after its mixed Q3 results? 🤔 Despite opening new centers and overseas growth, DVA lost 12.8% over six months, with ongoing concerns about reliance on commercial payers. However, its international expansion strategy and unique patient-centric model could drive future growth. Discover the full analysis here 👉 https://www.zacks.com/stock/news/2806065/heres-why-you-should-hold-davita-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2806065-body-25382&ADID=SYND_STOCKTWITS_TWEET_2_2806065_BODY_25382
0 · Reply
RyGuy_79
RyGuy_79 Dec. 18 at 1:51 PM
$CRMD $DVA I will actively avoid Davita for myself and my family members in the future so we don’t die from CRBSI due to their gross negligence.
0 · Reply
DrArmageddon
DrArmageddon Dec. 18 at 1:48 PM
$CRMD $DVA what are you waiting for DaVita : more mortality and more losing business. the business model of previous CEO is past and time to adopt innovative tool to boost your business. DaVita shareholders need to start emailing the management
0 · Reply
InvestorM
InvestorM Dec. 18 at 1:33 PM
0 · Reply
Noname2022
Noname2022 Dec. 18 at 1:13 PM
$CRMD $DVA $FMS $AKBA “Based on CorMedix’s analysis of the data available through September 30, 2025, compared to historical controls, use of DefenCath demonstrated an overall 72% reduction in CRBSI, and a 70% reduction in hospitalizations secondary to CRBSI.“ https://www.globenewswire.com/news-release/2025/12/18/3207654/0/en/CorMedix-Therapeutics-Announces-Positive-Data-From-Ongoing-Real-World-Evidence-Study-of-DefenCath.html
0 · Reply
Noname2022
Noname2022 Dec. 17 at 8:41 PM
$DVA $AKBA Average DVA patient on 16 medicarions per CIO, whats one more #patientcompliance https://www.healthcareittoday.com/2025/12/01/cio-podcast-episode-104-leveraging-ai-with-madhu-narasimhan/
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 3:19 AM
Actionable Trade Alert for $DVA: Market Context: $DVA closed at $117.94, below the 30-day (MA30) and 50-day (MA50) moving averages, indicating a bearish short-term trend. The RSI at 43.97 suggests the stock is nearing oversold conditions, which may signal a potential reversal. Directional Bias: Given the proximity to the 60-day low ($113.97) and the current RSI, there is a possibility for a bounce back towards the MA30 and MA50. However, caution is warranted as the stock remains below key moving averages. Trade Plan: - Suggested Entry: $118.00 - Stop Loss: $113.50 (approximately 4.25% below entry) - Take Profit Targets: 1. $121.00 (2.54% gain) 2. $124.00 (5.08% gain) 3. $138.00 (16.95% gain) With a potential for over 17% ROI on the third target, this trade offers a favorable risk-reward ratio. Monitor closely for market sentiment shifts. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 6:51 AM
Actionable Trade Alert for $DVA: Market Context: $DVA closed at $121.35, showing a stable position within its recent trading range. The RSI at 54.49 indicates a neutral momentum, suggesting potential for upward movement. The stock is currently above the 30-day moving average (MA30) of $119.52 but below the 50-day moving average (MA50) of $122.58, indicating a possible bullish reversal. Directional Bias: With the 60-day high at $134.59 and low at $113.97, there is room for growth. The current price is closer to the high, suggesting upward potential. The ATR of 2.33 indicates moderate volatility, allowing for reasonable price movements. Trade Plan: - Suggested Entry: $121.50 - Stop Loss: $118.00 (approximately 2% below entry) - Take Profit Targets: 1. $125.00 (3.1% ROI) 2. $128.50 (5.9% ROI) 3. $142.00 (17% ROI) This plan aims for a conservative entry with significant upside potential. https://privateprofiteers.com
0 · Reply
Noname2022
Noname2022 Dec. 14 at 12:03 PM
$CRMD $AKBA $DVA $FMS How much DOs currently spend on drugs per FFS treatment Figure reimbursement is about ~$280/treatment currently (FFS)
1 · Reply
Noname2022
Noname2022 Dec. 13 at 4:17 PM
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 12 at 1:40 PM
$DVA RSI: 65.45, MACD: -1.2647 Vol: 2.10, MA20: 118.70, MA50: 122.80 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 11:45 PM
Actionable Trade Alert for $DVA: Market Context: $DVA closed at $121.69, showing a strong bullish momentum with an RSI of 68.14, indicating it is nearing overbought territory. The price is above the 30-day moving average (MA30) of $119.48 but below the 50-day moving average (MA50) of $122.83, suggesting a potential resistance level. Directional Bias: The current price is closer to the 60-day high of $134.59, indicating bullish sentiment. However, the RSI suggests caution as it approaches overbought levels. Trade Plan: - Suggested Entry: $121.70 - Stop Loss: $118.50 (approximately 2% below entry) - Take Profit Targets: 1. $125.00 (Target 1: 2.7% ROI) 2. $128.50 (Target 2: 5.5% ROI) 3. $142.00 (Target 3: 16.6% ROI) This strategy offers a potential 17%+ ROI on the third target while maintaining a manageable risk. https://privateprofiteers.com
0 · Reply
Noname2022
Noname2022 Dec. 11 at 11:03 PM
$CRMD $DVA “Next chapter of growth and innovation” maybe they can educate their CMO on defencath…
1 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 3:49 AM
Actionable Trade Alert for $DVA: Market Context: $DVA closed at $116.67, positioned between its 60D high of $134.59 and low of $113.97. The RSI at 50.39 indicates a neutral market, suggesting potential for upward movement. The price is below both the 30-day MA of $120.01 and the 50-day MA of $123.33, indicating a bearish trend in the short term. Directional Bias: The current price is approaching the 60D low, which could act as a support level. A break above the MA30 could signal a reversal. Trade Plan: - Suggested Entry: $117.00 (breakout above MA30) - Stop Loss: $113.50 (below 60D low) - Take Profit Targets: 1. $122.00 (MA30) 2. $126.00 (MA50) 3. $137.00 (17% ROI from entry) Monitor the trade closely, especially around MA levels for potential reversals. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Noname2022
Noname2022 Dec. 9 at 11:40 PM
1 · Reply
Noname2022
Noname2022 Dec. 9 at 6:11 PM
0 · Reply
Noname2022
Noname2022 Dec. 9 at 3:37 PM
$AKBA $DVA Post is aging like a fine wine… chef’s kiss
3 · Reply
Noname2022
Noname2022 Dec. 9 at 1:56 PM
$AKBA $DVA “You talk about volumes offsetting price declines. I’m not certain it’s going to offset”. “there could be a drop in revenue in 2027” Starting at 6:50 time marker… https://ir.akebia.com/events/event-details/piper-sandler-37th-annual-healthcare-conference
1 · Reply